Bank of New York Mellon
HRTX icon

Bank of New York Mellon’s Heron Therapeutics HRTX Stock Holding History

Bank of New York Mellon’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$169K Sell
395,838
-10,968
-3% -$8.79K ﹤0.01% 4169
2026
Q1 		$325K Sell
406,806
-11,671
-3% -$13.5K ﹤0.01% 3816
2025
Q4 		$544K Buy
418,477
+6,003
+1% +$7.41K ﹤0.01% 3561
2025
Q3 		$520K Buy
412,474
+10,363
+3% +$16.4K ﹤0.01% 3566
2025
Q2 		$832K Buy
402,111
+73,769
+22% +$151K ﹤0.01% 3226
2025
Q1 		$722K Sell
328,342
-12,368
-4% -$24K ﹤0.01% 3248
2024
Q4 		$521K Sell
340,710
-29
-0% -$47 ﹤0.01% 3501
2024
Q3 		$678K Sell
340,739
-108,473
-24% -$259K ﹤0.01% 3345
2024
Q2 		$1.57M Buy
449,212
+113,655
+34% +$349K ﹤0.01% 2933
2024
Q1 		$929K Sell
335,557
-68,813
-17% -$173K ﹤0.01% 3196
2023
Q4 		$687K Buy
404,370
+50,975
+14% +$56.1K ﹤0.01% 3382
2023
Q3 		$364K Buy
353,395
+19,345
+6% +$27.5K ﹤0.01% 3713
2023
Q2 		$387K Sell
334,050
-1,179
-0.4% -$2.1K ﹤0.01% 3719
2023
Q1 		$506K Sell
335,229
-14,186
-4% -$35.5K ﹤0.01% 3488
2022
Q4 		$874K Buy
349,415
+1,779
+0.5% +$5.73K ﹤0.01% 3258
2022
Q3 		$1.47M Buy
347,636
+36,285
+12% +$142K ﹤0.01% 3020
2022
Q2 		$869K Buy
311,351
+6,618
+2% +$26.6K ﹤0.01% 3290
2022
Q1 		$1.74M Buy
304,733
+5,882
+2% +$43K ﹤0.01% 3014
2021
Q4 		$2.73M Sell
298,851
-32,986
-10% -$337K ﹤0.01% 2799
2021
Q3 		$3.55M Buy
331,837
+32,251
+11% +$393K ﹤0.01% 2666
2021
Q2 		$4.65M Sell
299,586
-40,888
-12% -$650K ﹤0.01% 2536
2021
Q1 		$5.52M Sell
340,474
-14,891
-4% -$265K ﹤0.01% 2408
2020
Q4 		$7.52M Sell
355,365
-2,749
-0.8% -$47.8K ﹤0.01% 2157
2020
Q3 		$5.31M Sell
358,114
-11,045
-3% -$172K ﹤0.01% 2183
2020
Q2 		$5.43M Buy
369,159
+13,604
+4% +$223K ﹤0.01% 2173
2020
Q1 		$4.17M Sell
355,555
-7,799
-2% -$147K ﹤0.01% 2166
2019
Q4 		$8.54M Buy
363,354
+28,982
+9% +$641K ﹤0.01% 2068
2019
Q3 		$6.19M Buy
334,372
+24,602
+8% +$453K ﹤0.01% 2175
2019
Q2 		$5.76M Buy
309,770
+12,030
+4% +$240K ﹤0.01% 2260
2019
Q1 		$7.28M Sell
297,740
-325
-0.1% -$8.51K ﹤0.01% 2149
2018
Q4 		$7.73M Sell
298,065
-15,247
-5% -$419K ﹤0.01% 2057
2018
Q3 		$9.92M Buy
313,312
+13,928
+5% +$519K ﹤0.01% 2032
2018
Q2 		$11.6M Buy
299,384
+19,966
+7% +$636K ﹤0.01% 1941
2018
Q1 		$7.71M Buy
279,418
+78,719
+39% +$1.79M ﹤0.01% 2123
2017
Q4 		$3.63M Sell
200,699
-3,296
-2% -$53.7K ﹤0.01% 2508
2017
Q3 		$3.29M Sell
203,995
-862
-0.4% -$13.5K ﹤0.01% 2540
2017
Q2 		$2.84M Buy
204,857
+14,086
+7% +$204K ﹤0.01% 2634
2017
Q1 		$2.86M Buy
190,771
+40,657
+27% +$563K ﹤0.01% 2629
2016
Q4 		$1.97M Buy
150,114
+182
+0.1% +$2.86K ﹤0.01% 2864
2016
Q3 		$2.58M Buy
149,932
+1,946
+1% +$36.1K ﹤0.01% 2605
2016
Q2 		$2.67M Buy
147,986
+4,579
+3% +$89.4K ﹤0.01% 2548
2016
Q1 		$2.72M Sell
143,407
-4,066
-3% -$80.2K ﹤0.01% 2475
2015
Q4 		$3.94M Buy
147,473
+27,004
+22% +$722K ﹤0.01% 2349
2015
Q3 		$2.94M Buy
120,469
+5,441
+5% +$181K ﹤0.01% 2516
2015
Q2 		$3.58M Sell
115,028
-36,151
-24% -$680K ﹤0.01% 2562
2015
Q1 		$2.2M Buy
151,179
+45,618
+43% +$514K ﹤0.01% 2794
2014
Q4 		$1.06M Sell
105,561
-2,030
-2% -$16.6K ﹤0.01% 3269
2014
Q3 		$896K Buy
107,591
+23,321
+28% +$217K ﹤0.01% 3354
2014
Q2 		$1.04M Buy
+84,270
New +$1.01M ﹤0.01% 3286

Other funds holding HRTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CPC
Congress Park Capital Saratoga Springs, New York $370M AUM 26.01% 1-Year Est. Return
RB
Richmond Brothers Jackson, Michigan $192M AUM 23.02% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
CWP
Curated Wealth Partners El Segundo, California $774M AUM 5.71% 1-Year Est. Return

Bank of New York Mellon's HRTX Position: Q2 2026 in Review

Bank of New York Mellon reduced its Heron Therapeutics (HRTX) stake by 2.7% in Q2 2026, selling an estimated $8.79K and leaving 395,838 shares worth $169K. The position accounts for ﹤0.01% of the portfolio, ranked #4169.

Bank of New York Mellon first reported a position in HRTX in Q2 2014 and has held it in 49 quarters since. The position peaked at $11.6M in Q2 2018. 83 funds tracked by Wall St. Rank hold HRTX as of Q2 2026.

  • Bank of New York Mellon held 395,838 shares of Heron Therapeutics worth $169K as of Q2 2026.
  • Bank of New York Mellon sold 10,968 Heron Therapeutics shares in Q2 2026, an estimated $8.79K.
  • Heron Therapeutics made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #4169 holding.
  • Bank of New York Mellon first reported a position in Heron Therapeutics in Q2 2014 and has held it in 49 quarters since.
  • Bank of New York Mellon's Heron Therapeutics position peaked at $11.6M in Q2 2018.
  • 83 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.